HealthEconomics.Com welcomed CEO of Evidence and Access Dr. Jeff Anderson and Senior Director of Strategic Market Access Dr. Rosemary Jose of OPEN Health to share their thoughts as industry leaders. They discussed key trends relating to market access, health economics and outcomes research (HEOR), and real world evidence (RWE). Dr. Jose notes that pharmaceutical companies should consider market access earlier in the drug development pipeline while Dr. Anderson highlighted the importance of a patient-centered approach.
Dr. Anderson remarks, “The acute focus on value has not abated. The absolute need to ensure assets represent value to a multitude of stakeholders, including patients and healthcare systems, is ever more real in a world of tighter healthcare budgets and the explosion of more targeted and specialized therapies. It is critical that the evidence supporting these assets reflects the evolving healthcare landscape as well as appeals to regulators and decision makers. This means effectively showcasing the asset’s real value to patients, healthcare systems and practitioners, and society at large.” Read more here.
(Source: HealthEconomics.Com, 6/3/21)
